Not yet recruitingInterventionalPhase 1Last updated Aug 13, 2026

CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Overview

ClinicalTrials.gov ID: NCT07763938
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityOTHER
Brief Summary: Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Nov 1, 2026Estimated
Primary Completion Date: Dec 30, 2029Estimated
Completion Date: Dec 30, 2032Estimated

Study Record Dates

First Submitted: Aug 9, 2026
First Submitted that Met QC Criteria: Aug 9, 2026
First Posted: Aug 13, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 9, 2026
Last Update Posted: Aug 13, 2026Actual
Last Verified: Aug 2026

NCT07002112Recruiting

The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

NCT04260932Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

NCT05585996Unknown status

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

NCT06503094Unknown status

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

NCT04260945Completed

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

NCT06735495Recruiting

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors